India’s pharmaceutical industry is at a crossroads. The CDSCO’s serialisation mandate isn’t just another compliance checkbox. It’s forcing manufacturers to rethink how they protect their brands, track their products, and deal with counterfeits. And right now, choosing the right serialisation solution provider in India is anything but simple.
You’ve got vendors throwing around promises of 3-month implementations, ‘industry-leading’ platforms, the works. Some of it’s real. Most of it isn’t. How do you figure out who’s actually solving your problem versus who’s just selling you a pitch?
This guide walks you through exactly what matters when evaluating a serialisation solution provider India, and what questions separate serious manufacturers from the rest.
Back in August 2023, India’s CDSCO fundamentally changed the rules. The Top 300 pharmaceutical brands had to implement serialisation across all new batches. This wasn’t optional. It wasn’t “by next year.” It was immediate and enforceable.
Here’s what actually shifted:
The mandate requires item-level serialisation on primary packaging. Each unit, every blister, vial, carton needs a unique, trackable identifier. That identifier connects to centralized databases that log product movement from manufacturing through to the pharmacy.
Regulators have increased their focus on product authentication and anti-counterfeiting measures. For brands covered under Schedule H2, manufacturers should ensure that packaging labels meet the applicable QR/barcode requirements and that the encoded information is accurate, readable, and audit-ready. This isn’t theoretical enforcement. It’s happening now.
If your brand is among India’s Top 300 pharmaceutical manufacturers by market value, you’re already covered. But “covered” doesn’t mean exempt; it means mandatory.
The scope is specific: all batches manufactured on or after August 1, 2023, must carry serialisation. Every drug form, tablets, capsules, injections, syrups, everything falls under this requirement.
Non-compliance may expose a covered manufacturer to regulatory review or enforcement action under applicable drug regulations, depending on the facts of the case. Avoid specifying penalties such as licence suspension unless confirmed by legal or regulatory counsel.
Smaller manufacturers outside the Top 300 face increasing pressure to implement the same standards voluntarily. It’s not officially required yet, but the writing’s on the wall. First-movers gain a competitive advantage; laggards eventually get forced to catch up.
The Schedule H2 requirement applies to the packaging label of notified drug formulation brands. Where there is insufficient space on the primary packaging label, the barcode or QR code may be printed or affixed on the secondary packaging label.
Manufacturers should evaluate their primary and secondary packaging formats during implementation so the code remains readable, durable, and compliant across SKUs. Manufacturers who have only solved primary packaging serialisation will face another scramble.
The smart move? Choose a pharma track and trace solution provider who builds secondary packaging into their roadmap from day one. Don’t invest in a system that only handles primary; you’ll be back at square one rebuilding in two years.
Not all serialisation solutions are equal. Some vendors slap QR codes on packages and call it done. Others build genuine serialization pharmaceutical solutions that actually solve the problem.
Here’s what separates the two:
Your solution must assign a unique serialisation code to every individual unit not batch-level codes, item-level. Each blister, each vial, each carton gets its own identifier.
That identifier needs to follow GS1 standards. Why? Because global supply chains run on GS1. If you’re exporting, your distributors in other markets expect GS1-compliant codes. Non-compliant systems create friction at every handoff.
The code itself matters. Different authentication architectures have different trade-offs. Database-based systems can support real-time status checks, event history, and recall workflows, while encryption-based or code-embedded approaches may reduce dependence on continuous connectivity. Manufacturers should evaluate both models based on auditability, uptime, integration complexity, verification workflow, and regulatory requirements.
Real pharmaceutical serialization solutions handle the complete hierarchy. A blister goes into a carton. Cartons go into cases. Cases go on pallets. Each level needs its own serialisation tied to the level below it.
This isn’t theoretical. Wholesalers and distributors use aggregation data to verify that the cases they received actually contain the cartons they ordered. Counterfeiters break down at this level, they can’t easily replicate aggregation hierarchies.
A serialisation solution provider India that only handles primary packaging leaves you vulnerable at the secondary and tertiary levels. That’s where gray market diversion happens.
Serialisation is supply-chain infrastructure. But consumers need verification too.
The best solutions integrate consumer-facing QR verification directly into the serialisation system. A customer scans a code, gets instant authenticity confirmation, and sees batch information. No separate apps. No clunky lookup databases.
This drives consumer behavior change. Once people know they can verify, they start scanning. Once counterfeiters realize consumers are verifying, the economics of counterfeiting collapse.
Your serialisation system must feed regulatory systems directly. For export markets, manufacturers may need reporting capabilities that align with market-specific frameworks such as the U.S. DSCSA or EU FMD.
For India’s Schedule H2 requirement, the immediate focus is on ensuring that the barcode or QR code stores the required product and manufacturing information for authentication. Any claims about real-time CDSCO reporting should be used only if supported by current regulatory guidance.
A real pharmaceutical serialization solution includes APIs that push data to regulatory systems automatically. It handles CDSCO requirements, EU FMD reporting, US DSCSA data, and other market-specific mandates all from one platform.
This separates vendors who understand pharmaceutical compliance from vendors who don’t.
You’re in conversations with vendors. They’re pitching their India serialisation solution provider services. Here’s exactly what to ask:
This is where most solutions break down. Carton serialisation is relatively straightforward. But what about loose syringes? Vials without external packaging? Blister packs where serialisation needs to be on the blister itself?
Ask: “Can your system serialize at the individual unit level for syringes, vials, loose tablets, and all product formats we manufacture?”
If a vendor requires customization, ask for a clear explanation of the scope, validation steps, timeline, cost impact, and examples of similar formats they have implemented. Customization is common in pharmaceutical packaging, but it should be transparent and well-documented.
Real solutions handle every format because pharmaceutical products come in every format.
Here’s where the gap between marketing and reality opens up.
Vendors who claim “3-month implementation” haven’t touched a real production line. Ask how they’ll roll this out:
That’s realistic for a single line. If you’re a multi-site manufacturer? Add months.
Ask about downtime requirements. How long does your line stop during implementation? What’s the validation process? What happens when something breaks?
Vendors who give you vague timelines are hiding real complexity.
Serialisation inside your factory is one thing. Tracking products from distributor to wholesaler to pharmacy is another.
A real pharma track and trace solution provider builds visibility beyond your factory walls. They provide portals where distributors can verify products. They track temperature exposure for cold-chain medicines. They identify gray market diversions early.
Ask: “Show me your distributor verification interface. How do wholesalers confirm they received authorized stock? How do you flag unauthorized sales?”
If they can’t show you working distributor portals, they’re not solving track and trace. They’re just encoding data.
We’ve worked with 700+ pharmaceutical production lines across India. We built psID® specifically for Indian manufacturers facing CDSCO mandates and global export complexity.
Here’s what that means in practice:
psID® handles item-level encoding at your production line using TruTrak® hardware that integrates with existing equipment; no line replacement needed.
According to approved product documentation, psID® can generate unique product codes designed for authentication and traceability workflows. Any claims about encryption, offline verification, or immediate verification should be reviewed against PharmaSecure’s approved technical and marketing materials before publication.
From there, the system tracks product movement through distributors and wholesalers. Retailers can verify the stock source. Consumers scan and verify authenticity. Regulators get real-time data on product movement and counterfeiting incidents.
All from one integrated platform.
Here’s what a real rollout looks like:
This is an illustrative timeline for a relatively straightforward single-line rollout. Actual timelines can vary based on packaging-line readiness, product formats, validation requirements, ERP integration, artwork changes, site approvals, and regulatory documentation.
1. Who are the leading pharmaceutical serialisation solution providers in India?
You’re looking for vendors with proven production line integrations (not pilots), experience with CDSCO compliance, and demonstrated track records with mid-to-large manufacturers.
PharmaSecure has 700+ line installations and 15+ years in this space. Manufacturers should evaluate providers based on documented pharmaceutical experience, production-line integrations, validation support, references, service capability, and ability to support applicable domestic and export-market requirements.
Ask for references, review implementation documentation, and speak with existing customers where possible.
2. Is pharma track and trace the same as serialisation?
No. Serialisation assigns unique identifiers to products. Track and trace follow those products through the supply chain. You need both working together.
Serialisation answers “Which unit is this?” Track and trace answers “Where has this unit been?”
A complete solution integrates both.
3. How long does serialisation implementation take for a mid-size manufacturer?
Realistically, 90 days for a single production line, assuming you’re not replacing hardware. If you’re serializing multiple products or formats across multiple lines, just add 30-60 days per additional line. Your timeline really depends on your equipment, how complex your products are, and how fast regulators move.
Many mid-size projects are planned in phases. A single-line implementation may be completed faster than a multi-site rollout, but the final timeline should be confirmed after a line assessment, validation review, artwork review, and integration scoping.
4. Does India’s Top 300 mandate cover export products?
The Schedule H2 QR/barcode requirement applies to the notified top 300 drug formulation brands under the Drugs Rules, 1945. Export products may also be subject to destination-market requirements such as EU FMD, U.S. DSCSA, or other national traceability rules. Manufacturers should confirm applicability for export-only SKUs with regulatory counsel or the relevant licensing authority.
Export markets have their own serialisation requirements (EU FMD, US DSCSA, etc.), so you’re probably serializing anyway. The CDSCO mandate just makes it mandatory for domestic and export simultaneously.
We’ll check your current production setup, find exactly where you’re losing serialization coverage, and then build a roadmap that fits your products and regulatory rules.
No sales pitch. Just actionable insight.
Contact us today
pharmasecure seo / April 6, 2026
pharmasecure seo / March 23, 2026
pharmasecure seo / March 11, 2026
PharmaSecure is a global track-and-trace, product authentication and consumer engagement company that has helped protect billions of packages through its technology-enabled solutions. Our proven serialization capabilities have enabled large pharmaceutical companies to meet different traceability requirements.
©2025, PharmaSecure Inc. All Rights Reserved.
